Tag: cyclophosphamide
Cyclophosphamide: Trade name Cytoxan, a chemotherapy drug. Cyclophosphamide is an alkylating agent frequently used in combination with anthracyclines (Adriamycin, epirubicin) and/or taxanes (Taxol, Taxotere).
News
- 07/09/12
- Orange flavonoid hesperidin could interfere with cyclophosphamide
- 02/15/12
- Grapes might help protect against Adriamycin-induced heart damage
- 12/07/11
- Modern chemotherapy reduces BC death by about a third
- 12/10/10
- Adding zoledronic acid to chemotherapy does not improve markers
Studies
-
Glycemic load impacts the response of acquired resistance in breast cancer cells to chemotherapeutic drugs in vitro
Cite
Adham SA, Al Kalbani A, Al Zeheimi N, Al Dalali M, Al Kharusi N, Siddiqi A, et al. Glycemic load impacts the response of acquired resistance in breast cancer cells to chemotherapeutic drugs in vitro. PLOS ONE. Public Library of Science (PLoS); 2024; 19:e0311345 10.1371/journal.pone.0311345
-
Cyclophosphamide- and doxorubicin-induced impairment of high affinity choline uptake and spatial memory can be prevented by dietary choline supplementation in breast tumor bearing mice
Cite
Botelho R, Kirstein CL, Philpot RM. Cyclophosphamide- and doxorubicin-induced impairment of high affinity choline uptake and spatial memory can be prevented by dietary choline supplementation in breast tumor bearing mice. PLOS ONE. Public Library of Science (PLoS); 2024; 19:e0305365 10.1371/journal.pone.0305365
-
The Effect of High-Intensity Interval Training on Quality of Life and Incidence of Chemotherapy Side Effects in Women With Breast Cancer
Cite
Klavina A, Ceseiko R, Campa M, Jermolenko GF, Eglitis K, Llorente A, et al. The Effect of High-Intensity Interval Training on Quality of Life and Incidence of Chemotherapy Side Effects in Women With Breast Cancer. Integrative Cancer Therapies. SAGE Publications; 2024; 23 10.1177/15347354241297385
-
Potential of Natural Phenolic Compounds against Doxorubicin-Induced Chemobrain: Biological and Molecular Mechanisms Involved
Cite
Serini S, Calviello G. Potential of Natural Phenolic Compounds against Doxorubicin-Induced Chemobrain: Biological and Molecular Mechanisms Involved. Antioxidants. MDPI AG; 2024; 13:486 10.3390/antiox13040486
-
Dietary approaches for exploiting metabolic vulnerabilities in cancer
Cite
Menyhárt O, Győrffy B. Dietary approaches for exploiting metabolic vulnerabilities in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. Elsevier BV; 2023;:189062 10.1016/j.bbcan.2023.189062
-
Effectiveness of Nigella sativa Addition against TNF-Alpha in Stage III and IV Breast Cancer Undergoing Doxorubicin and Cyclophosphamide Chemotherapy at Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia
Cite
Friyoga Syahril , Wirdah A, Nur Qodir , Irfanuddin , Irsan Saleh , Yenny Dian Andayani , et al. Effectiveness of Nigella sativa Addition against TNF-Alpha in Stage III and IV Breast Cancer Undergoing Doxorubicin and Cyclophosphamide Chemotherapy at Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia. Bioscientia Medicina : Journal of Biomedicine and Translational Research. Hanif Medisiana Publisher; 2023; 8:4009-4014 10.37275/bsm.v8i2.924
-
Complementarity between Microbiome and Immunity May Account for the Potentiating Effect of Quercetin on the Antitumor Action of Cyclophosphamide in a Triple-Negative Breast Cancer Model
Cite
Manni A, Sun Y, Schell TD, Lutsiv T, Thompson H, Chen K, et al. Complementarity between Microbiome and Immunity May Account for the Potentiating Effect of Quercetin on the Antitumor Action of Cyclophosphamide in a Triple-Negative Breast Cancer Model. Pharmaceuticals. MDPI AG; 2023; 16:1422 10.3390/ph16101422
-
Açai Berry Attenuates Cyclophosphamide-Induced Damage in Genitourinary Axis-Modulating Nrf-2/HO-1 Pathways
Cite
Siracusa R, D’Amico R, Fusco R, Impellizzeri D, Peritore AF, Gugliandolo E, et al. Açai Berry Attenuates Cyclophosphamide-Induced Damage in Genitourinary Axis-Modulating Nrf-2/HO-1 Pathways. Antioxidants. MDPI AG; 2022; 11:2355 10.3390/antiox11122355
-
Vitamin D status in breast cancer cases following chemotherapy: A pre and post observational study in a tertiary hospital in Yogyakarta, Indonesia
Cite
Puspitaningtyas H, Sulistyoningrum DC, Witaningrum R, Widodo I, Hardianti MS, Taroeno-Hariadi KW, et al. Vitamin D status in breast cancer cases following chemotherapy: A pre and post observational study in a tertiary hospital in Yogyakarta, Indonesia. PLOS ONE. Public Library of Science (PLoS); 2022; 17:e0270507 10.1371/journal.pone.0270507
-
Can Exposure to Environmental Pollutants Be Associated with Less Effective Chemotherapy in Cancer Patients?
Cite
Lagunas-Rangel FA, Liu W, Schiöth HB. Can Exposure to Environmental Pollutants Be Associated with Less Effective Chemotherapy in Cancer Patients?. International Journal of Environmental Research and Public Health. MDPI AG; 2022; 19:2064 10.3390/ijerph19042064
-
Insights into the Protective Effects of Thymoquinone against Toxicities Induced by Chemotherapeutic Agents
Cite
Farooq J, Sultana R, Taj T, Asdaq SMB, Alsalman AJ, Mohaini MA, et al. Insights into the Protective Effects of Thymoquinone against Toxicities Induced by Chemotherapeutic Agents. Molecules. MDPI AG; 2021; 27:226 10.3390/molecules27010226
-
Chemotherapy-Induced Changes in the Lung Microenvironment: The Role of MMP-2 in Facilitating Intravascular Arrest of Breast Cancer Cells
Cite
Middleton JD, Sivakumar S, Hai T. Chemotherapy-Induced Changes in the Lung Microenvironment: The Role of MMP-2 in Facilitating Intravascular Arrest of Breast Cancer Cells. International Journal of Molecular Sciences. MDPI AG; 2021; 22:10280 10.3390/ijms221910280
-
Focal white matter microstructural alteration after anthracycline-based systemic treatment in long-term breast cancer survivors: a structural magnetic resonance imaging study
Cite
Zhang H, Li P, Liu T, Wang X, Feng W, Chen R, et al. Focal white matter microstructural alteration after anthracycline-based systemic treatment in long-term breast cancer survivors: a structural magnetic resonance imaging study. Brain Imaging and Behavior. Springer Science and Business Media LLC; 2021; 10.1007/s11682-021-00551-3
-
Epigallocatechin gallate and theaflavins independently alleviate cyclophosphamide-induced ovarian damage by inhibiting the overactivation of primordial follicles and follicular atresia
Cite
Chen Q, Xu Z, Li X, Du D, Wu T, Zhou S, et al. Epigallocatechin gallate and theaflavins independently alleviate cyclophosphamide-induced ovarian damage by inhibiting the overactivation of primordial follicles and follicular atresia. Phytomedicine. Elsevier BV; 2021;:153752 10.1016/j.phymed.2021.153752
-
Cyclophosphamide-free Adjuvant Chemotherapy for the Potential Prevention of Premature Ovarian Insufficiency and Infertility in Young Women with Breast Cancer
Cite
Lambertini M, Partridge AH. Cyclophosphamide-free Adjuvant Chemotherapy for the Potential Prevention of Premature Ovarian Insufficiency and Infertility in Young Women with Breast Cancer. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2021; 10.1093/jnci/djab066
-
Cognitive Impairment Resulting from Treatment with Docetaxel, Doxorubicin, and Cyclophosphamide
Cite
Brown T, McElroy T, Simmons P, Walters H, Ntagwabira F, Wang J, et al. Cognitive Impairment Resulting from Treatment with Docetaxel, Doxorubicin, and Cyclophosphamide. Brain Research. Elsevier BV; 2021;:147397 10.1016/j.brainres.2021.147397
-
Impact of Exercise on Chemotherapy Tolerance and Survival in Early-Stage Breast Cancer: A Nonrandomized Controlled Trial
Cite
Kirkham AA, Gelmon KA, Van Patten CL, Bland KA, Wollmann H, McKenzie DC, et al. Impact of Exercise on Chemotherapy Tolerance and Survival in Early-Stage Breast Cancer: A Nonrandomized Controlled Trial. Journal of the National Comprehensive Cancer Network. Harborside Press, LLC; 2020; 18:1670-1677 10.6004/jnccn.2020.7603
-
Paclitaxel-induced peripheral neuropathy in early-stage breast cancer patients.
Cite
Liu J, Sorooshian H. Paclitaxel-induced peripheral neuropathy in early-stage breast cancer patients.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2020; 38:e12503-e12503 10.1200/jco.2020.38.15_suppl.e12503
-
Thymoquinone Augments Cyclophosphamide-Mediated Inhibition of Cell Proliferation in Breast Cancer Cells
Cite
Khan A, Aldebasy YH, Alsuhaibani SA, Khan MA. Thymoquinone Augments Cyclophosphamide-Mediated Inhibition of Cell Proliferation in Breast Cancer Cells. Asian Pacific Journal of Cancer Prevention. EpiSmart Science Vector Ltd; 2019; 20:1153-1160 10.31557/apjcp.2019.20.4.1153
-
Apoptosis induced by luteolin in breast cancer: Mechanistic and therapeutic perspectives
Cite
Ahmed S, Khan H, Fratantonio D, Hasan MM, Sharifi S, Fathi N, et al. Apoptosis induced by luteolin in breast cancer: Mechanistic and therapeutic perspectives. Phytomedicine. Elsevier BV; 2019; 59:152883 10.1016/j.phymed.2019.152883
-
Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: a cohort study
Cite
van der Willik KD, Koppelmans V, Hauptmann M, Compter A, Ikram MA, Schagen SB. Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: a cohort study. Breast Cancer Research. Springer Science and Business Media LLC; 2018; 20 10.1186/s13058-018-1062-3
-
Efficacy of scalp cooling in reducing alopecia in early breast cancer patients receiving contemporary chemotherapy regimens
Cite
Chan A, Bauwens A, Pontre S, Jackson S, McGlone F, Ernenwein T, et al. Efficacy of scalp cooling in reducing alopecia in early breast cancer patients receiving contemporary chemotherapy regimens. The Breast. Elsevier BV; 2018; 41:127-132 10.1016/j.breast.2018.07.006
-
Rutin, a Quercetin Glycoside, Restores Chemosensitivity in Human Breast Cancer Cells
Cite
Iriti M, Kubina R, Cochis A, Sorrentino R, Varoni EM, Kabała-Dzik A, et al. Rutin, a Quercetin Glycoside, Restores Chemosensitivity in Human Breast Cancer Cells. Phytotherapy Research. Wiley; 2017; 31:1529-1538 10.1002/ptr.5878
-
Cyclophosphamide leads to persistent deficits in physical performance and in vivo mitochondria function in a mouse model of chemotherapy late effects
Cite
Crouch M, Knowels G, Stuppard R, Ericson NG, Bielas JH, Marcinek DJ, et al. Cyclophosphamide leads to persistent deficits in physical performance and in vivo mitochondria function in a mouse model of chemotherapy late effects. PLOS ONE. Public Library of Science (PLoS); 2017; 12:e0181086 10.1371/journal.pone.0181086
-
Role of taxanes in chemotherapy-related cognitive impairment: A prospective longitudinal study
Cite
Cerulla N, Arcusa À, Navarro J, Garolera M, Enero C, Chico G, et al. Role of taxanes in chemotherapy-related cognitive impairment: A prospective longitudinal study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 164:179-187 10.1007/s10549-017-4240-6
-
Weight change during chemotherapy in breast cancer patients: a meta-analysis
Cite
van den Berg M, Winkels R, de Kruif J, van Laarhoven H, Visser M, de Vries J, et al. Weight change during chemotherapy in breast cancer patients: a meta-analysis. BMC Cancer. Springer Science and Business Media LLC; 2017; 17 10.1186/s12885-017-3242-4
-
Ovarian protection in cyclophosphamide-treated mice by fennel
Cite
Hassanpour A, Yousefian S, Askaripour M, Sharififar F, Ezzatabadipour M. Ovarian protection in cyclophosphamide-treated mice by fennel. Toxicology Reports. Elsevier BV; 2017; 4:160-164 10.1016/j.toxrep.2017.03.002
-
Time-of-Day Dictates Transcriptional Inflammatory Responses to Cytotoxic Chemotherapy
Cite
Borniger JC, Walker II WH, Gaudier-Diaz MM, Stegman CJ, Zhang N, Hollyfield JL, et al. Time-of-Day Dictates Transcriptional Inflammatory Responses to Cytotoxic Chemotherapy. Scientific Reports. Springer Science and Business Media LLC; 2017; 7 10.1038/srep41220
-
Cyclophosphamide promotes breast cancer cell migration through CXCR4 and matrix metalloproteinases
Cite
Hung C, Hsu Y, Chen T, Chang C, Lee M. Cyclophosphamide promotes breast cancer cell migration through CXCR4 and matrix metalloproteinases. Cell Biology International. Wiley; 2017; 41:345-352 10.1002/cbin.10726
-
Serum IL-6 level as a predictor of response to neo-Adjuvant chemotherapy in patients of breast carcinoma
Cite
Mittal P, Gupta N, Goswami B. Serum IL-6 level as a predictor of response to neo-Adjuvant chemotherapy in patients of breast carcinoma. Hellenic Journal of Surgery. Springer Science and Business Media LLC; 2016; 88:306-310 10.1007/s13126-016-0338-2
-
Protective Effects of Essential Oils as Natural Antioxidants against Hepatotoxicity Induced by Cyclophosphamide in Mice
Cite
Sheweita SA, El-Hosseiny LS, Nashashibi MA. Protective Effects of Essential Oils as Natural Antioxidants against Hepatotoxicity Induced by Cyclophosphamide in Mice. PLOS ONE. Public Library of Science (PLoS); 2016; 11:e0165667 10.1371/journal.pone.0165667
-
Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin–cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study
Cite
Thamlikitkul L, Srimuninnimit V, Akewanlop C, Ithimakin S, Techawathanawanna S, Korphaisarn K, et al. Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin–cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study. Supportive Care in Cancer. Springer Science and Business Media LLC; 2016; 25:459-464 10.1007/s00520-016-3423-8
-
Cardioprotective Effect of Selenium Against Cyclophosphamide-Induced Cardiotoxicity in Rats
Cite
Gunes S, Sahinturk V, Karasati P, Sahin IK, Ayhanci A. Cardioprotective Effect of Selenium Against Cyclophosphamide-Induced Cardiotoxicity in Rats. Biological Trace Element Research. Springer Science and Business Media LLC; 2016; 177:107-114 10.1007/s12011-016-0858-1
-
Chemotherapy Agents Alter Plasma Lipids in Breast Cancer Patients and Show Differential Effects on Lipid Metabolism Genes in Liver Cells
Cite
Sharma M, Tuaine J, McLaren B, Waters DL, Black K, Jones LM, et al. Chemotherapy Agents Alter Plasma Lipids in Breast Cancer Patients and Show Differential Effects on Lipid Metabolism Genes in Liver Cells. PLOS ONE. Public Library of Science (PLoS); 2016; 11:e0148049 10.1371/journal.pone.0148049
-
The Dietary Flavonoid Fisetin Causes Cell Cycle Arrest, Caspase-Dependent Apoptosis, and Enhanced Cytotoxicity of Chemotherapeutic Drugs in Triple-Negative Breast Cancer Cells
Cite
Smith ML, Murphy K, Doucette CD, Greenshields AL, Hoskin DW. The Dietary Flavonoid Fisetin Causes Cell Cycle Arrest, Caspase-Dependent Apoptosis, and Enhanced Cytotoxicity of Chemotherapeutic Drugs in Triple-Negative Breast Cancer Cells. Journal of Cellular Biochemistry. Wiley; 2016; 117:1913-1925 10.1002/jcb.25490
-
Renoprotective effect of Mangifera indica polysaccharides and silymarin against cyclophosphamide toxicity in rats
Cite
Amien AI, Fahmy SR, Abd-Elgleel FM, Elaskalany SM. Renoprotective effect of Mangifera indica polysaccharides and silymarin against cyclophosphamide toxicity in rats. The Journal of Basic & Applied Zoology. Elsevier BV; 2015; 72:154-162 10.1016/j.jobaz.2015.09.006
-
The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study
Cite
de Groot S, Vreeswijk MP, Welters MJ, Gravesteijn G, Boei JJ, Jochems A, et al. The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study. BMC Cancer. Springer Science and Business Media LLC; 2015; 15 10.1186/s12885-015-1663-5
-
Benzyl butyl phthalate increases the chemoresistance to doxorubicin/cyclophosphamide by increasing breast cancer-associated dendritic cell-derived CXCL1/GROα and S100A8/A9
Cite
HSU Y, HUNG J, TSAI E, WU C, HO Y, JIAN S, et al. Benzyl butyl phthalate increases the chemoresistance to doxorubicin/cyclophosphamide by increasing breast cancer-associated dendritic cell-derived CXCL1/GROα and S100A8/A9. Oncology Reports. Spandidos Publications; 2015; 34:2889-2900 10.3892/or.2015.4307
-
Cardiac assessment of early breast cancer patients 18years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy
Cite
de Azambuja E, Ameye L, Diaz M, Vandenbossche S, Aftimos P, Hernández SB, et al. Cardiac assessment of early breast cancer patients 18years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy. European Journal of Cancer. Elsevier BV; 2015; 51:2517-2524 10.1016/j.ejca.2015.08.011
-
A mixture of honey bee products ameliorates the genotoxic side effects of cyclophosphamide
Cite
Fahmy MA, Hassan NHA, El-Fiky SA, Elalfy HG. A mixture of honey bee products ameliorates the genotoxic side effects of cyclophosphamide. Asian Pacific Journal of Tropical Disease. Elsevier BV; 2015; 5:638-644 10.1016/s2222-1808(15)60904-5
-
Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)
Cite
Ligibel JA, Cirrincione CT, Liu M, Citron M, Ingle JN, Gradishar W, et al. Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2015; 107 10.1093/jnci/djv179
-
Doxorubicin and cyclophosphamide treatment produces anxiety-like behavior and spatial cognition impairment in rats: Possible involvement of hippocampal neurogenesis via brain-derived neurotrophic factor and cyclin D1 regulation
Cite
Kitamura Y, Hattori S, Yoneda S, Watanabe S, Kanemoto E, Sugimoto M, et al. Doxorubicin and cyclophosphamide treatment produces anxiety-like behavior and spatial cognition impairment in rats: Possible involvement of hippocampal neurogenesis via brain-derived neurotrophic factor and cyclin D1 regulation. Behavioural Brain Research. Elsevier BV; 2015; 292:184-193 10.1016/j.bbr.2015.06.007
-
Modulation of Murine Breast Tumor Vascularity, Hypoxia, and Chemotherapeutic Response by Exercise
Cite
Betof AS, Lascola CD, Weitzel D, Landon C, Scarbrough PM, Devi GR, et al. Modulation of Murine Breast Tumor Vascularity, Hypoxia, and Chemotherapeutic Response by Exercise. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2015; 107 10.1093/jnci/djv040
-
Rutin ameliorates cyclophosphamide induced oxidative stress and inflammation in Wistar rats: Role of NFκB/MAPK pathway
Cite
Nafees S, Rashid S, Ali N, Hasan SK, Sultana S. Rutin ameliorates cyclophosphamide induced oxidative stress and inflammation in Wistar rats: Role of NFκB/MAPK pathway. Chemico-Biological Interactions. Elsevier BV; 2015; 231:98-107 10.1016/j.cbi.2015.02.021
-
Risk of Hospitalization According to Chemotherapy Regimen in Early-Stage Breast Cancer
Cite
Barcenas CH, Niu J, Zhang N, Zhang Y, Buchholz TA, Elting LS, et al. Risk of Hospitalization According to Chemotherapy Regimen in Early-Stage Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014; 32:2010-2017 10.1200/jco.2013.49.3676
-
Citrus Limonin Lacks the Antichemotherapeutic Effect in Human Models of Breast Cancer
Cite
Somasundaram S, Price J, Pearce K, Shuck R, Jayaprakasha G, Patil B. Citrus Limonin Lacks the Antichemotherapeutic Effect in Human Models of Breast Cancer. Journal of Nutrigenetics and Nutrigenomics. S. Karger AG; 2012; 5:106-114 10.1159/000336921
-
Hesperidin Inhibits Cyclophosphamide-Induced Tumor Growth Delay in Mice
Cite
Hosseinimehr SJ, Jalayer Z, Naghshvar F, Mahmoudzadeh A. Hesperidin Inhibits Cyclophosphamide-Induced Tumor Growth Delay in Mice. Integrative Cancer Therapies. SAGE Publications; 2012; 11:251-256 10.1177/1534735412448959
-
Surgery for widely disseminated breast cancer: prolonged control by excision of metastases
Cite
Rees GJ, Britton DC, Malcolm GP, Rees M. Surgery for widely disseminated breast cancer: prolonged control by excision of metastases. JRSM Short Reports. SAGE Publications; 2012; 3:1-4 10.1258/shorts.2012.011162
-
Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer
Cite
Swain SM, Jeong J, Geyer CE, Costantino JP, Pajon ER, Fehrenbacher L, et al. Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer. New England Journal of Medicine. Massachusetts Medical Society; 2010; 362:2053-2065 10.1056/nejmoa0909638
-
Neuropsychological Performance in Survivors of Breast Cancer More Than 20 Years After Adjuvant Chemotherapy
Cite
Koppelmans V, Breteler MM, Boogerd W, Seynaeve C, Gundy C, Schagen SB. Neuropsychological Performance in Survivors of Breast Cancer More Than 20 Years After Adjuvant Chemotherapy. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2012; 30:1080-1086 10.1200/jco.2011.37.0189
-
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
Cite
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) . Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. The Lancet. Elsevier BV; 2012; 379:432-444 10.1016/s0140-6736(11)61625-5
-
Twenty-five year results of the national cancer institute randomized breast conservation trial
Cite
Simone NL, Dan T, Shih J, Smith SL, Sciuto L, Lita E, et al. Twenty-five year results of the national cancer institute randomized breast conservation trial. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 132:197-203 10.1007/s10549-011-1867-6
-
Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer
Cite
Han Y, Yu Z, Wen S, Zhang B, Cao X, Wang X. Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 131:483-490 10.1007/s10549-011-1799-1
-
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Cite
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. New England Journal of Medicine. Massachusetts Medical Society; 2011; 365:1273-1283 10.1056/nejmoa0910383
-
Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer
Cite
Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, et al. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer. Wiley; 2011; 118:2385-2393 10.1002/cncr.26555
-
Synchronous Chemo-radiation Can Reduce Local Recurrence in Early Stage Breast Cancer: Results of the SECRAB Trial (ISRCTN: 84214355) Presented on Behalf of the SECRAB Steering Committee
Cite
Fernando I, Bowden S, Brookes C, Grieve R, Spooner D, Agrawal R, et al. Synchronous Chemo-radiation Can Reduce Local Recurrence in Early Stage Breast Cancer: Results of the SECRAB Trial (ISRCTN: 84214355) Presented on Behalf of the SECRAB Steering Committee. European Journal of Cancer. Elsevier BV; 2011; 47:2 10.1016/s0959-8049(11)70097-1
-
Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers
Cite
Lee LJ, Alexander B, Schnitt SJ, Comander A, Gallagher B, Garber JE, et al. Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer. Wiley; 2011; 117:3093-3100 10.1002/cncr.25911
-
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology
Cite
Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. Wiley; 2011; 13:1-10 10.1093/eurjhf/hfq213
-
Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer
Cite
Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer. Wiley; 2012; 118:5937-5946 10.1002/cncr.27527
-
Abstract P1-11-01: ANZAC: A Randomised Neoadjuvant Biomarker Study Investigating the Anti-Tumour Activity of the Addition of Zoledronic Acid to Chemotherapy in Breast Cancer
Cite
Winter M, Syddall S, Cross S, Evans A, Ingram C, Jolley I, et al. Abstract P1-11-01: ANZAC: A Randomised Neoadjuvant Biomarker Study Investigating the Anti-Tumour Activity of the Addition of Zoledronic Acid to Chemotherapy in Breast Cancer. Poster Session Abstracts. American Association for Cancer Research; 2010; 10.1158/0008-5472.sabcs10-p1-11-01
-
Hematologic toxicity with adjuvant docetaxel and cyclophosphamide in early breast cancer.
Cite
Santos FN, Cruz MR, Cezana L, Costa LA, de Azevedo CA, De Barros E Silva MJ, et al. Hematologic toxicity with adjuvant docetaxel and cyclophosphamide in early breast cancer.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:e11081-e11081 10.1200/jco.2010.28.15_suppl.e11081
-
Hepatotoxicity in breast cancer patients post-chemotherapy with docetaxel, doxorubucin, and cyclophosphamide.
Cite
Wills SM, Reid R, Jaiyesimi IA, Margolis JH. Hepatotoxicity in breast cancer patients post-chemotherapy with docetaxel, doxorubucin, and cyclophosphamide.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:e11031-e11031 10.1200/jco.2010.28.15_suppl.e11031
-
Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer
Cite
Cameron DA, Massie C, Kerr G, Leonard RCF. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. British Journal of Cancer. Springer Science and Business Media LLC; 2003; 89:1837-1842 10.1038/sj.bjc.6601366
-
Abstract 3223: Severe dietary restriction enhances cancer treatment: Protecting normal cells and sensitizing malignant cells to chemotherapy by fasting
Cite
Lee C, Safdie F, Raffaghello L, Wei M, Longo V. Abstract 3223: Severe dietary restriction enhances cancer treatment: Protecting normal cells and sensitizing malignant cells to chemotherapy by fasting. Cellular and Molecular Biology. American Association for Cancer Research; 2010; 10.1158/1538-7445.am10-3223
-
Decrease in Breast Density in the Contralateral Normal Breast of Patients Receiving Neoadjuvant Chemotherapy: MR Imaging Evaluation
Cite
Chen J, Nie K, Bahri S, Hsu C, Hsu F, Shih H, et al. Decrease in Breast Density in the Contralateral Normal Breast of Patients Receiving Neoadjuvant Chemotherapy: MR Imaging Evaluation. Radiology. Radiological Society of North America (RSNA); 2010; 255:44-52 10.1148/radiol.09091090
-
Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer
Cite
Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, et al. Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2009; 27:3297-3302 10.1200/jco.2009.19.6410
-
Antigenotoxic effect of apigenin against anti-cancerous drugs
Cite
Siddique YH, Beg T, Afzal M. Antigenotoxic effect of apigenin against anti-cancerous drugs. Toxicology in Vitro. Elsevier BV; 2008; 22:625-631 10.1016/j.tiv.2007.12.002
-
Influence of orange juice over the genotoxicity induced by alkylating agents: an in vivo analysis
Cite
Franke SIR, Prá D, Erdtmann B, Henriques JAP, da Silva J. Influence of orange juice over the genotoxicity induced by alkylating agents: an in vivo analysis. Mutagenesis. Oxford University Press (OUP); 2005; 20:279-283 10.1093/mutage/gei034